Therapeutic Hypothermia in Neonatal Hypoxic-Ischemic Encephalopathy
- 201 Downloads
Purpose of Review
Therapeutic hypothermia reduces death or disability in term and near-term infants with moderate-severe hypoxic-ischemic encephalopathy. Nevertheless, many infants still survive with disability, despite hypothermia, supporting further research in to ways to further improve neurologic outcomes.
Recent clinical and experimental studies have refined our understanding of the key parameters for hypothermic neuroprotection, including timing of initiation, depth, and duration of hypothermia, and subsequent rewarming rate. However, important knowledge gaps remain. There is encouraging clinical evidence from a small phase II trial that combined treatment of hypothermia with recombinant erythropoietin further reduces risk of disability but definitive studies are still needed.
In conclusion, recent studies suggest that current protocols for therapeutic hypothermia are near-optimal, and that the key to better neurodevelopmental outcomes is earlier diagnosis and initiation of hypothermia after birth. Further research is essential to find and evaluate ways to further improve outcomes after hypoxic-ischemic encephalopathy, including add-on therapies for therapeutic hypothermia and preventing pyrexia during labor and delivery.
KeywordsNeonatal encephalopathy Therapeutic hypothermia Neonatal neuroprotection Fetal sheep Erythropoietin Neonatal examination
The authors’ work reported in this review has been supported by grants from the Health Research Council of New Zealand, New Zealand Lottery Grants Board, the Auckland Medical Research Foundation, the Neurological Foundation of New Zealand, the Norwegian Research Council, and the Moulton Foundation UK.
Compliance with Ethical Standards
Conflict of Interest
Laura Bennet, Joanne Davidson, Simerdeep Dhillon, Marianne Thoresen, Guido Wassink and Kelly Zhou each declare no potential conflicts of interest. Alistair J. Gunn reports a US patent 6,986,783 issued. Patent held by the University of Auckland.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 6.Jacobs S, Hunt R, Tarnow-Mordi W, Inder T, Davis P. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev. 2003;4:CD003311.Google Scholar
- 10.•• Davidson JO, Wassink G, Yuill CA, Zhang FG, Bennet L, Gunn AJ. How long is too long for cerebral cooling after ischemia in fetal sheep? J Cereb Blood Flow Metab. 2015;35(5):751–8 Systematic study in fetal sheep showing that continuing hypothermia for 5 days instead of 3 days does not further improve outcomes and may be deleterious. CrossRefGoogle Scholar
- 11.•• Davidson JO, Draghi V, Whitham S, Dhillon SK, Wassink G, Bennet L, et al. How long is sufficient for optimal neuroprotection with cerebral cooling after ischemia in fetal sheep? J Cereb Blood Flow Metab. 2018;38(6):1047–59 Systematic study in fetal sheep showing that hypothermia must be continued for 72 hours for optimal benefit. CrossRefGoogle Scholar
- 19.Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev. 2013;1:CD003311.Google Scholar
- 27.• Wassink G, Davidson JO, Lear CA, Juul SE, Northington F, Bennet L, et al. A working model for hypothermic neuroprotection. J Physiol. 2018. https://doi.org/10.1113/JP274928 Systematic discussion of a framework to understand neuroprotection with therapeutic hypothermia.
- 28.•• Shankaran S, Laptook AR, Pappas A, McDonald SA, Das A, Tyson JE, et al. Effect of depth and duration of cooling on death or disability at age 18 months among neonates with hypoxic-ischemic encephalopathy: a randomized clinical trial. JAMA. 2017;318(1):57–67 Very important, large randomized controlled trial showing that longer or deeper cooling does not further improve outcomes after neonatal encephalopathy. CrossRefGoogle Scholar
- 31.• Liu X, Jary S, Cowan F, Thoresen M. Reduced infancy and childhood epilepsy following hypothermia-treated neonatal encephalopathy. Epilepsia. 2017;58(11):1902–11 Cohort study suggesting reduced risk of epilepsy in children treated with therapeutic hypothermia for neonatal encephalopathy. CrossRefGoogle Scholar
- 36.• Wood T, Osredkar D, Puchades M, Maes E, Falck M, Flatebo T, et al. Treatment temperature and insult severity influence the neuroprotective effects of therapeutic hypothermia. Sci Rep. 2016;6:23430 Systematic, well controlled study in P7 rats demonstrating the adverse effects of pyrexia after hypoxia-ischemia. CrossRefGoogle Scholar
- 49.• Davidson JO, Wassink G, Draghi V, Dhillon SK, Bennet L, Gunn AJ. Limited benefit of slow rewarming after cerebral hypothermia for global cerebral ischemia in near-term fetal sheep. J Cereb Blood Flow Metab. 2018:271678X18791631. Controlled study in fetal sheep suggesting that duration of therapeutic hypothermia after severe hypoxia-ischemia is more important that the rate of rewarming. Google Scholar
- 50.• Laptook AR, Shankaran S, Tyson JE, Munoz B, Bell EF, Goldberg RN, et al. Effect of therapeutic hypothermia initiated after 6 hours of age on death or disability among newborns with hypoxic-ischemic encephalopathy: A randomized clinical trial. JAMA. 2017;318(16):1550–60 Large randomized controlled trial that suggests limited benefit if hypothermia is delayed outside of its known window of opportunity. CrossRefGoogle Scholar
- 61.•• Chalak LF, Nguyen KA, Prempunpong C, Heyne R, Thayyil S, Shankaran S et al. Prospective research in infants with mild encephalopathy identified in the first six hours of life: neurodevelopmental outcomes at 18–22 months. Pediatr Res. 2018 https://doi.org/10.1038/s41390-018-0174-x/. Accessed 13 Sep 2018.. Prospective cohort study quantifying the risk of disability and neurodevelopmental impairment after mild neonatal encephalopathy.
- 62.•• Murray DM, O’Connor CM, Ryan CA, Korotchikova I, Boylan GB. Early EEG grade and outcome at 5 years after mild neonatal hypoxic ischemic encephalopathy. Pediatrics. 2016;138(4) Cohort study showing similar risk of long term disabilty in infants with formally characterized mild and moderate encephalopathy. Google Scholar
- 63.Davidson JO, Battin M, Gunn AJ. Evidence that therapeutic hypothermia should be continued for 72 hours. Arch Dis Child Fetal Neonatal Ed. 2018:fetalneonatal-2018-315844.Google Scholar
- 64.• Lally PJ, Montaldo P, Oliveira V, Swamy RS, Soe A, Shankaran S, et al. Residual brain injury after early discontinuation of cooling therapy in mild neonatal encephalopathy. Arch Dis Child Fetal Neonatal Ed. 2018;103(4):F383–F7 Small cohort study highlighting high rate of brain injury on magnetic resonance imaging in infants with mild encephalopathy who were rewarmed prematurely. CrossRefGoogle Scholar
- 68.• Azzopardi D, Robertson NJ, Bainbridge A, Cady E, Charles-Edwards G, Deierl A, et al. Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial. Lancet Neurol. 2016;15(2):145–53 Innovative randomized controlled trial showing no benefit from the combination of xenon plus hypothermia on magnetic resonance measured outcomes. CrossRefGoogle Scholar
- 73.• Wu YW, Mathur AM, Chang T, McKinstry RC, Mulkey SB, Mayock DE, et al. High-dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy: A phase II trial. Pediatrics. 2016;137(6):e20160191 A well conducted phase II trial showing benefit from combined treatement with erythropoeitin and hypothermia for neonatal encephalopathy. CrossRefGoogle Scholar